SUMMARY
The radioprotective substances amifostine (WR-2721) and cystamine were tested in rats following
their parenteral administration (i.p., i.m., and i.v.). Cystamine is more toxic than amifostine in
mice as well as in rats. Amifostine was less toxic after intravenous injection. The radioprotective
effects of WR-2721 (160 mg.kg-1) and cystamine (40 mg.kg-1) were not significant when they
were administered parenterally 15-20 mins before lethal doses of whole body fission neutron
irradiation in the thermal column of reactor VVR-S and 30-days lethality served as an integral
criterion of postradiation injury to the rat body. The fission neutrons spectrum was characterized
by mean energy 0.9-1.0 MeV with 30-40% fluency participation of moderate (E=0.1 MeV)
neutrons. The contamination with gamma rays was 22-30%; the dose rate of whole irradiation was
within 0.3 to 0.8 Gy.min-1.
KEY WORDS
amifostine; WR-2721; cystamine; radioprotective effect; fission neutrons irradiation
REFERENCES
Ferle-Vidovic A, Petrovic D, Vidic Z, Osmak M,
Kadija K: Absence of AET protection against
fast neutrons: cellular effects. Radiat Environ
Biophys 19:197-203, 1981.
Genes VS: Tables of significant differences
between groups of observations according to
quality indicators (in Russian). Meditsina,
Moscow 1964.
Kuna P: Radioprotective effectivness of cystamine
administered intramuscularly to mice (in
Russian). Radiobiologya, 22, 1982:517-519.
Kuna P: Appearance of radioprotective effect of
gammaphos (WR-2721) in mice (in Czech). Cas
Lek ces 121, 1982a:912-914.
Kuna P: Duration and degree of radioprotection of
WR-2721 in mice following its intraperitoneal,
intramuscular and subcutaneous administration.
Radiobiol Radiother (Berlin), 24, 1983:357-364.
Kuna P: Radioprotection of small intestine and
spleen hemopoiesis by gammaphos (WR-2721)
or cystamine in whole body gamma irradiated
mice. Biologia (Bratislava), 39, 1983:273-282.
Kuna P: Chemical radioprotection (in Czech).
Avicenum, Praha 1985, pp. 148. (Translated into
Russian: Meditsina, Moscow 1989, pp. 190).
Kuna P, Dostal M, Neruda O, Petyrek P, Svoboda V, Resl M, Prouza Z, Hermanska J, Spurny F, Listik E, Pitterman P, Knajfl J, Simsa J, Spelda S, Podzimek F: Radioprotective
effects of gammaphos (WR-2721) and cystamine
in the case of whole-body irradiation of mice by
fission neutrons (in Czech). Sborn lek (Praha)
90:110-116, 1988.
Kuna P, Krajcovic C: Acute toxicity and
radioprotective effectiveness of gammaphos
(WR-2721) in rats (in Czech). Cas Lek ces
120:776-778, 1981.
Kuna P, Neruda O, Navratil L, Matzner J,
Ziskova R: Nuclear Terrorism. J Appl
Biomed 1:55-59, 2003.
Kuna P, Volenec K, Vodicka I, Dostal M:
Radioprotective and hemodynamic effects of
WR-2721 and cystamine in rats: Time course
studies. Neoplasma 30:349-357, 1983.
Langendroff H, Langendorff M, Metzner R,
Monig H, Steinbach K-H, Temme W,
Tumbragel G: Radiobiological investigations
with fast neutrons. II. The radioprotective action
of different substances on male mice.
Atomkernergie 18:83-88, 1971.
Piper JR, Stringfellow CR, Elliot RD,
Johnston TP: S-2-(3-aminoalkylamino)ethyl
dihydrogen phosphorothioates and related
compounds as potential antiiradiation agents.
J Med Chem 12:236-243, 1969.
Pospisil M: Pharmacological radiation protection.
In: Baumstark-Khan C et al. (eds.).
Fundamentals for the assessment of risks from
environmental radiation. Kluwer Academic
Publishers, The Netherlands 1999, pp. 411-420.
Roth Z, Josifko M, Maly V, Trcka V: Statistical
methods in experimental medicine (in Czech).
Statni zdravotnicke nakladatelstvi, 1962, pp.
589.
Sedlmeier H, Metzger E, Jentzsch U,
Weitzenegger E: Schutzeffekt von
Aminoprolylamino-athylthiophosphat (WR-2721) bei Neutronen-, Gamma- oder
Rontgenbestrahlung von Mausen.
Strahlentherapie 157:685-691, 1981.
Sigdestad CP, Connor AM, Scott RM: Effect of
chemical protectors on the response of the
intestine to roentgen or fission neutron
irradiation. Acta Radiol Ther Phys Biol 15:401-409, 1976.
Sigdestad CP, Grdina DJ, Connor AM,
Hanson WR: A comparison of radioprotection
from three neutron cources and 60Co by WR-2721 and WR-151327. Radiat Res 106:224-233, 1986.
Sigdestad CP, Connor AM, Sims CS:
Modification of neutron-induced hematopoietic
effects by chemical radioprotectors. Int J
Radiat Oncol Biol Phys 22:807-811, 1992.
Suchter LM, Hensley ML, Meropol NJ, Winer EP: 2002 update of recommendations for the
use of chemotherapy and radiotherapy
protectants: Clinical Practice Guidelines of the
American society of clinical oncology. J Clin
Oncol 20:2895-2903, 2002.
Sverdlov AG: Biological effects of neutrons and
chemical protection (in Russian). Nauka,
Leningrad 1974, pp. 224.
|
CITED
Vavrova J, Rezacova M, Pejchal J. Fullerene nanoparticles and their anti-oxidative effects: a comparison to other radioprotective agents. J Appl Biomed. 10: 1-8, 2012.
|
